55 results
8-K
EX-99.1
NUVL
Nuvalent Inc - Ordinary Shares
9 May 24
Nuvalent Highlights Pipeline Progress, Reiterates Key Anticipated Milestones, and Reports First Quarter 2024 Financial Results
6:37am
broader front-line development strategy for its ALK program in 2024.
HER2 Program
Nuvalent presented new preclinical data at AACR supporting the broad … with advanced ALK-positive NSCLC with registrational intent;
oLaunch the front-line development strategy for its ALK program;
oPresent interim data from
8-K
EX-99.1
NUVL
Nuvalent Inc - Ordinary Shares
27 Feb 24
Nuvalent Highlights Pipeline Progress, Reiterates Key Anticipated Milestones and Reports Fourth Quarter and Full Year 2023 Financial Results
6:38am
the ALKOVE-1 trial at a medical meeting and to outline its broader front-line development strategy for its ALK program in 2024.
HER2 Program … launch. At Nuvalent, Mr. Metivier has built and led our Human Resources capabilities and facilitated our people and culture strategy to ensure we optimize
8-K
EX-99.1
0l8k0fl3ur da662k9
9 Jan 24
Nuvalent Announces “OnTarget 2026” Operating Plan and Key Anticipated Milestones
4:40pm
8-K
EX-99.1
iwhibp5h
14 Nov 23
Nuvalent Highlights Corporate and Pipeline Achievements and Reports Third Quarter
6:45am
8-K
24w1zoi dip
17 Oct 23
Nuvalent Announces Pricing of Public Offering of Common Stock
4:07pm
8-K
EX-99.1
izqb4fhpzqh8a7pu9v9
17 Oct 23
Nuvalent Announces Pricing of Public Offering of Common Stock
4:07pm
424B5
cst46vymmq wq9
17 Oct 23
Prospectus supplement for primary offering
4:05pm
424B5
oiulpn6 a4v
16 Oct 23
Prospectus supplement for primary offering
7:39am
8-K
8iuel0tn 6b43xmxw
13 Oct 23
Nuvalent Reports Preliminary Phase 1 Clinical Data from ALKOVE-1 Trial
6:40am
8-K
EX-99.1
fnw3pm8d f83ks2f
13 Oct 23
Nuvalent Reports Preliminary Phase 1 Clinical Data from ALKOVE-1 Trial
6:40am
8-K
EX-99.1
plt4kbj
4 Oct 23
Other Events
4:05pm
8-K
q59ogep ho8a4g
4 Oct 23
Other Events
4:05pm
8-K
EX-99.1
72d 8x6yfm6b5pf04etg
10 Aug 23
Nuvalent Highlights Pipeline Progress and Reports Second Quarter 2023 Financial Results
6:45am
8-K
EX-99.1
ig0mc
11 May 23
Nuvalent Announces Anticipated Timing of Preliminary Phase 1 Dose-Escalation Data for NVL-655 and Reports First Quarter 2023 Financial Results
6:39am